Provided is a drug/cancer treatment method that combines a compound exhibiting MDM2 inhibitory activity and a compound exhibiting BTK inhibitory activity. The provided drug or combined treatment method is obtained by combining: (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridine-4-yl)-4,4-dimethyl-2"-oxo-1",2"-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide, or a pharmaceutically acceptable salt thereof； and ibrutininb or a pharmaceutically acceptable salt thereof.提供一種組合具有MDM2抑制活性的化合物及具有BTK抑制活性的化合物而成的醫藥/癌症之治療方法。提供一種組合(3’R,4’S,5’R)-N-[(3R,6S)-6-胺甲醯基四氫-2H-哌喃-3-基]-6”-氯-4’-(2-氯-3-氟吡啶-4-基)-4,4-二甲基-2”-側氧-1”,2”-二氫二螺[環己烷-1,2’-吡咯啶-3’,3”-吲哚]-5’-羧醯胺或其藥學上可容許的鹽與依魯替尼(Ibrutinib)或其藥學上可容許的鹽而成的醫藥或併用治療方法。
